Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive, Safety), By Therapeutic Area (Oncology, Neurology), By Phase, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Biomarker Discovery Outsourcing Services Market Growth & Trends

The global biomarker discovery outsourcing services market size is expected to reach USD 41.27 billion by 2030, growing at a CAGR of 19.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market.

Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth. Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research.

Biomarker Discovery Outsourcing Services Market Report Highlights

• Based on biomarker type, the surrogate endpoints segment accounted for the largest revenue share of 54.88% in 2024.
• Based on therapeutic areas, the market includes oncology, neurology, cardiology, autoimmune diseases, and others.
• Based on the discovery phase, in 2024, the biomarker identification segment accounted for the largest revenue share in the market.
• Based on end use, the market is segmented into pharmaceutical companies, biotechnology companies, and others.
• The biomarker discovery outsourcing services industry in North America accounted for the largest market share of 43.96% in 2024.